ReviewNanoscale advances2025
The evolution of integrated magnetic hyperthermia and chemodynamic therapy for combating cancer: a comprehensive viewpoint.
Review in Nanoscale advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Recent Advances in Ferrite-Based Materials for Biomedical Applications: A Comprehensive Review.Advanced materials (Deerfield Beach, Fla.) · 2026Review
- Advances and Prospects in MOF-Based Platforms for Tumor Hyperthermia.Bioengineering (Basel, Switzerland) · 2026Review
- Spatiotemporal cancer controlNanomedicine (London, England) · 2026Review
- Next-generation dynamic and combinatorial nanotherapies for liver cancer: mechanisms, current advances and future perspectives.Journal of nanobiotechnology · 2026Review
- Therapeutic Metal Ions: Engineering Biomaterials for Multimodal Disease Treatment.International journal of nanomedicine · 2026Review
- Predictors of Successful Whole-Body Hyperthermia in Cancer Patients: Target Temperature Achievement and Safety Analysis.Cancers · 2025Article
- Dual-Function Biomaterials for Postoperative Osteosarcoma: Tumor Suppression and Bone Regeneration.Research (Washington, D.C.) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Magnetic hyperthermia therapy (MHT) and chemodynamic therapy (CDT) are emerging non-invasive cancer treatments that leverage reactive oxygen species (ROS) to induce tumor cell death. While MHT uses magnetic nanoparticles to generate localized heat under an alternating magnetic field, its efficacy can be limited by low ROS levels in hypoxic tumor microenvironments. CDT complements MHT by inducing toxic hydroxyl radicals through Fenton reactions, enhancing ROS production and antitumor effects. This mini-review discusses the synergistic potential of combining MHT with CDT using multifunctional nanomaterials, offering insights into enhanced ROS-mediated cancer therapy and future directions for clinical applications.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.